Bioequivalence of dienogest as a single component and dienogest in combination with estradiol valerate after single administration to healthy postmenopausal women

Drugs of Today

Volumn 37, Issue SUPPL. G, 2001, Pages 75-86

  Zimmermann, H ^a   Maibauer, R ^a   Schutt B ^a   Benda, N ^a   Kaufmann, G ^a   Pidun, A ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; ESTRADIOL VALERATE; LAFAMME;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; POSTMENOPAUSE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET;

EID: 0034791932     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. A 19-norprogestin without 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view
2. A 19-norprogestin without 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view
3. Experimentelle endokrinpharmakologie von dienogest
4. The pharmacological profile of dienogest
5. Dienogest
6. Zur pharmakokinetik und biotransformation von dienogest bet verschiedenen tierspezies
7. Dienogest: Bindungsstudien an verschiedenen rezeptorund serumproteinen
8. Pharmacokinetics of estradiol valerate 2 mg + dienogest 2 mg (Climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women
9. Effect of STS 557 on blood hormone levels, the testis, accessory sex organs and fertility of rats
10. Pharmakokinetik von dienogest als monopräparat und in kombination mit ethinylestradiol
11. Studies on non-protein bound dienogest in plasma of different species
12. Non-protein bound dienogest in serum and salivary dienogest in women taking the oral contraceptives Certostat® and Valette®
13. Studies on pharmacokinetics of STS 557 in animal species and man
14. Studies on the biotransformation of the progestagen dienogest in the rabbit
15. Studies on biotransformation of STS 557
16. Metabolite patterns obtained by HPLC of the new progestagen dienogest
17. The new progestagen dienogest: Effects and metabolism
18. Der Einfluβ von dienogest auf das humane cytochrom P-450-enzymsystem in vitro
19. Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinyl estradiol
20. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation
21. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence of treatment on free and total testosterone, levels in the serum
22. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum
23. Levonorgestrel. Clinical pharmacokinetics
24. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women
25. Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: Pharmacokinetics and pharmacodynamic parameters
26. Pharmacokinetics of oestrogens and progestogens
27. Comparative pharmacology of newer progestogens
28. Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women